Abstract
To identify pretreatment prognostic factors for patients with castration-resistant prostate cancer (CRPC) undergoing docetaxel (DCT) chemotherapy. We retrospectively analyzed 102 patients with CRPC who underwent DCT chemotherapy (dosage: 60-75 mg/m(2)) from December 2001 to August 2013. The parameters evaluated as prognostic factors were as follows: age, body mass index, Gleason score, clinical TNM stage, prior radical prostatectomy, prior radiation therapy, performance status, presence of pain, laboratory results at the start of DCT, and prostate-specific antigen (PSA) kinetics during prior androgen deprivation therapy (ADT), including PSA level at the start of ADT (PSA-ADT), PSA half-time (PSAT1/2), time to nadir, PSA level at nadir (PSA-Nadir), duration of nadir, PSA doubling time (PSADT), and PSA level at the start of DCT (PSA-DCT). Univariate and multivariate analyses were performed to identify independent prognostic factors. Median cancer-specific survival (CSS) duration following CRPC diagnosis was 28.0 months. In univariate analyses, performance status, serum albumin, serum creatinine, PSAT1/2, time to nadir, PSA-Nadir, duration of nadir, PSADT, and PSA-DCT showed a potential association with prognosis (P<0.001-0.077). ...Continue Reading
References
Feb 1, 1992·British Journal of Urology·S D FossåD W Newling
Dec 15, 1992·Cancer·D P PetrylakN L Geller
Jun 1, 1996·Urology·E D CrawfordC A Ross
Feb 26, 1999·Journal of the National Cancer Institute·H I ScherA B Kremer
Jun 7, 2002·The Journal of Urology·Charles Huggins, Clarence V Hodges
Jul 19, 2002·Cancer·David J SamsonNaomi Aronson
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oren SmaletzMichael W Kattan
Jan 9, 2004·International Journal of Cancer. Journal International Du Cancer·Juan MoroteJaume Reventos
Jul 13, 2004·The New England Journal of Medicine·Anthony V D'AmicoWilliam J Catalona
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Mar 25, 2005·Endocrine-related Cancer·A BerrutiL Dogliotti
Aug 13, 2005·The American Journal of Surgical Pathology·Jonathan I EpsteinUNKNOWN ISUP Grading Committee
Feb 23, 2007·Cancer·Anthony V D'AmicoMing-Hui Chen
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 20, 2009·Cancer·Toni K ChoueiriWilliam K Oh
Apr 18, 2009·The Journal of Urology·Yong Hyun ParkCheol Kwak
Jul 4, 2009·The Prostate·Kenji KurodaNeil H Bander
Oct 15, 2009·Cancer Research·Lu GanHaojie Huang
Sep 3, 2010·Cancer Research·Meng-Lei ZhuNatasha Kyprianou
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 5, 2010·Lancet·Johann Sebastian de BonoUNKNOWN TROPIC Investigators
Apr 20, 2011·Prostate Cancer and Prostatic Diseases·T SasakiA Hoshina
Jun 10, 2011·The Prostate·Shu-Pin HuangChun-Hsiung Huang
Sep 1, 2011·European Urology·Jerome P Richie
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Oct 13, 2012·Korean journal of urology·Seok Young HongSe Joong Kim
Dec 19, 2012·European Urology·Christopher J KetoStephen J Freedland
Apr 12, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y LoriotC Massard
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K L NoonanK N Chi
Aug 6, 2013·European Urology·John M Fitzpatrick, Ronald de Wit
Apr 30, 2014·BMC Urology·Atsushi TomiokaKiyohide Fujimoto